Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01956409
Other study ID # 201201056MIB
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received September 25, 2013
Last updated February 3, 2016
Start date September 2012
Est. completion date March 2017

Study information

Verified date February 2016
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Interventional

Clinical Trial Summary

The application of FCH PET in breast cancer diagnosis has not been reported.

We hypothesize that FCH reveals choline metabolic profiles of breast cancers, and shows the similar pathophysiological mechanism to choline on proton MRS, and our study goals are:

1. To investigate and compare the diagnostic performance of proton MRS and FCH PET for localized findings on mammography and breast ultrasound.

2. To investigate whether FCH PET findings are correlated with choline signals on proton MRS.

3. To evaluate if choline, water and lipid signals on proton MRS, FCH PET are associated with factors related to clinical outcome and prognosis- that is, molecular markers, tumor staging, histologic grade of breast cancers.

4. For localized advanced breast cancer, to investigate the treatment response to NAC using proton MRS and FCH PET, and to evaluate which modality is more sensitive.

5. To investigate the usefulness of FCH PET for whole body staging for breast cancer patients.


Description:

In recent years, the application of 18F-FDG PET (positron emission tomography) and MRI for breast lesion diagnosis was emerging. Imbriaco et al compared the diagnostic performance of 18F-FDG PET and MRI for suspicious breast lesions, with PET showing a sensitivity of 80% and specificity 100%; and MRI revealed a sensitivity of 95% and specificity of 98%. Lim et al studied 18F-FDG PET-CT with MRI to monitor treatment response for breast cancer patients receiving NAC, with a sensitivity 70% and specificity 72%, and can detect the treatment response earlier than conventional imaging.

However, 18F-FDG is not tumor specific, and searching for an alternative tracer agent as a tumor biomarker is necessary. 18F-Fluorocholine (FCH), a choline analog, was used for diagnosis of prostate cancer, hepatocellular carcinoma (HCC), bronchioloalveolar carcinoma, brain tumor, since malignant tumors show higher choline metabolites than benign lesions; it was reported that FCH PET showed higher sensitivity (88-94%) than 18F-FDG PET (59-68%) in detecting HCC. FCH PET was used for staging for prostate cancer, with FCH PET-CT can provide sufficient information for management with an accuracy of 88%.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date March 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

- Women aged 20-75 years old.

- with localized findings on mammography or breast ultrasound in recent 3 months and who will receive breast biopsy or excision for the findings; or with recently diagnosed LABC who will receive NAC.

Exclusion Criteria:

- unable to cooperate with the examinations

- pregnant or planning to be pregnant

- estimated GFR (eGFR) < 60 ml/min/1.73m2 or with recent acute renal failure, past history of renal dialysis.

- Past history of claustrophobia

- Past history of anaphylactoid reactions to MRI contrast agents or PET tracer agents.

- with cardiac pacemaker, aneurysmal clip, mechanical valve replacement, recently applied coronary artery stent (<2 months).

- Past history of breast cancer or other malignancy (treated within 5 years).

- lactating.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Drug:
18F-FCH

Magnevist


Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation the correlation of 18F-FCH PET and breast MRI 5 years No
Primary diagnostic accuracy of 18F-FCH PET for breast cancer diagnosis The investigators use the interpretation results of 18F-FCH PET for breast lesion diagnosis, with the pathology result of the breast lesions as gold standards, and to investigate how well the 18F-FCH PET can correctly diagnose the true nature of breast lesions. 5 years No
Secondary Monitoring of treatment response of breast cancer to chemotherapy using 18F-FCH PET For the breast cancer patients who will undergo chemotherapy treatment, we aim to use 18F-FCH PET before and after chemotherapy. And the changes of tracer uptake of 18F-FCH on PET scans before and after chemotherapy will be correlated with clinical outcomes before and after chemotherapy, to investigate whether 18F-FCH PET results can monitor treatment response of chemotherapy. 5 years No
Secondary diagnostic accuracy of breast MR spectroscopy for breast cancer diagnosis The investigators use the interpretation results of breast MRI (with MR spectroscopy in the examination) for breast lesion diagnosis, with the pathology result of the breast lesions as gold standards, and to investigate how well the breast MRI study can correctly diagnose the true nature of breast lesions. 5 years No
See also
  Status Clinical Trial Phase
Recruiting NCT03785171 - Predicative Value of Multimodal MRI in Moyamoya Disease
Not yet recruiting NCT03726788 - Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis Phase 2
Completed NCT01660841 - Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging Phase 3
Recruiting NCT03635619 - The Application of 3T MRI in Esophageal Cancer
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Recruiting NCT04555642 - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Recruiting NCT04850001 - Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
Not yet recruiting NCT05816213 - Point-of-care Low-field MRI in Acute Stroke
Active, not recruiting NCT05498623 - MR Fingerprinting for Diagnostic of Prostate Cancer
Recruiting NCT04996615 - Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Recruiting NCT04257747 - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI N/A
Recruiting NCT05889117 - Brain Stimulation for Concussion N/A
Completed NCT02540967 - Drug Use Investigation of Gadovist.
Completed NCT05103189 - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension N/A
Completed NCT02567318 - Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia? N/A
Recruiting NCT02834585 - Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT) N/A
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT01721785 - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer N/A
Completed NCT01223404 - Nicotinic Modulation of the Default Network N/A